News

Piramal Pharma has allotted 21 lakh equity shares under ESOP on 05 June 2026. Consequently, the paid up equity share capital has increased to Rs. 1,331,34,81,300 (consisting of 133,13,48,130 equity shares of face value of Rs. 10/- each).

Net loss of Piramal Pharma reported to Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2751.77 crore in the quarter ended March 2026 as against Rs 2754.07 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 325.94 crore in the year ended March 2026 as against net profit of Rs 91.13 crore during the previous year ended March 2025. Sales declined 3.08% to Rs 8869.08 crore in the year ended March 2026 as against Rs 9151.18 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2751.772754.07 0 8869.089151.18 -3 OPM %16.7420.37 -10.3915.79 - PBDT437.15515.56 -15 851.321230.98 -31 PBT218.77272.80 -20 20.08414.64 -95 NP-8.83153.50 PL -325.9491.13 PL Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 April 2026.

Piramal Pharma announced that US FDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Lexington, (Kentucky, USA) with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection.

Piramal Pharma announced the cessation of Subramanian Ramadorai (DIN: 00000002) as an independent director of the company with effect from 09 February 2026. Powered by Capital Market - Live News